2014 EAPM CAMPAIGN for EU Elections: STEPs – Specialised Treatment for Europe’s Patients

 Five STEPs towards a healthier Europe: Securing patients’ quality of life through Personalised Medicine

Steps cover

We call on decision-makers to commit to the following essential STEPs:

 

  •  STEP 1: Ensuring a regulatory environment which allows early patient access to novel and efficacious personalised medicine (PM)
  •  STEP 2: Increasing research and development for PM, while recognising its value
  •  STEP 3: Improving the education and training of healthcare professionals
  •  STEP 4: Supporting new approaches to reimbursement and HTA assessment, required for patient access to PM
  •  STEP 5: Increasing awareness and understanding of PM

 

 

 

 

euparliament

Statement by the European Parliament

One of our most important missions as politicians is to ensure that any citizen across the European Union fully enjoys his or her right for access to high quality health care and medical products.   We recognize that personalised medicine has the potential to realize the vision of being able to improve overall health  | Read the full statement

tonioBorg

Statement by EU Health Commissioner Tonio Borg

Personalised medicine is a promising concept.  As patients are divided into groups based on their individual, biological, genetic and genomic characteristics, medical interventions are tailored to those patients’ needs. | Read the full statement

EAPM2_155537

Statement by Irish Health Minister James Reilly

The European Alliance has been instrumental in bringing together key stakeholders to explore the potential of personalised medicine to provide solutions that are better tailored to the individual patient than traditional “one size fits all” medicinal products.  Read the full statement

rapport

2man

Click here to see: EAPM Position Statement
Support for IMI 2

Meeting the challenge

Healthcare practitioners need to access the right test at the right time and be in a position to correctly interpret the test result to identify the right treatment option. Therefore, it is important to consider the training needs of all clinicians so that they feel empowered by the additional information rather than overwhelmed by it

Patients will be empowered to take decisions on their own therapeutic management

Educated and empowered patients need to understand that a test may be necessary to decide on the right treatment, one that respects genetic difference

Educated and empowered patients need to understand that a test may be necessary to decide on the right treatment, one that respects genetic difference

 A patient-centred structure for risk communication should be developed in order to enhance patients’ awareness, competence and adherence to medicatio between people and molecular differences between diseases

What we Do

      • Allow early patient access to novel and efficacious personalised medicine
      • Increase research and development for personalised medicine
      • Improve the Education and Training of Healthcare Professionals
      • Acknowledge new approaches to reimbursement and health technology assessment
      • Increase awareness and understanding of personalised medicine